0002001011-24-000053.txt : 20240517 0002001011-24-000053.hdr.sgml : 20240517 20240517195950 ACCESSION NUMBER: 0002001011-24-000053 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240515 FILED AS OF DATE: 20240517 DATE AS OF CHANGE: 20240517 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Espinoza Octavio CENTRAL INDEX KEY: 0001905248 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33093 FILM NUMBER: 24962079 MAIL ADDRESS: STREET 1: C/O LIGAND PHARMACEUTICALS INC STREET 2: 3911 SORRENTO VALLEY BOULEVARD, STE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LIGAND PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000886163 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 770160744 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3911 SORRENTO VALLEY BLVD STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-550-7500 MAIL ADDRESS: STREET 1: 3911 SORRENTO VALLEY BLVD STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 edgardoc.xml PRIMARY DOCUMENT X0508 4 2024-05-15 0 0000886163 LIGAND PHARMACEUTICALS INC LGND 0001905248 Espinoza Octavio 555 HERITAGE DRIVE SUITE 200 JUPITER FL 33458 0 1 0 0 Chief Financial Officer 0 Common Stock 2024-05-15 4 S 0 5873 86.012 D 23882 D Common Stock 2024-05-16 4 S 0 2264 86.0034 D 21618 D Common Stock 2024-05-17 4 M 0 206 57.22 A 21824 D Common Stock 2024-05-17 4 M 0 1544 63.62 A 23368 D Common Stock 2024-05-17 4 M 0 145 68.74 A 23513 D Common Stock 2024-05-17 4 M 0 5022 52.84 A 28535 D Common Stock 2024-05-17 4 S 0 5022 86.6652 D 23513 D Common Stock 2024-05-17 4 S 0 134 86.6497 D 23379 D Employee Stock Option (right to buy) 57.22 2024-05-17 4 M 0 206 0.0 D 2030-10-01 Common Stock 206 7516 D Employee Stock Option (right to buy) 63.62 2024-05-17 4 M 0 1544 0.0 D 2032-12-13 Common Stock 1544 18456 D Incentive Stock Option (right to buy) 68.74 2024-05-17 4 M 0 145 0.0 D 2029-02-11 Common Stock 145 0 D Non-Qualified Stock Option (right to buy) 52.84 2024-05-17 4 M 0 5022 0.0 D 2032-05-05 Common Stock 5022 16179 D The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $86.0000 to $86.1500. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $86.0000 to $86.0350. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $86.0300 to $86.8200. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. As per the separation of OmniAb Inc. from the issuer, 4,096 stock options were vested and exercisable as of November 1, 2022, whereas 3,766 options vest in 23 substantially equal monthly installments beginning on December 1, 2022. Grant to reporting person of stock options that will vest and become exercisable over a 4-year period measured from December 5, 2022, with 12-1/2% of the shares subject to the stock options vesting on the date that is six months after December 5, 2022 and the remaining stock options vesting in 42 equal monthly installments thereafter. The stock option vests as to 50% of the underlying shares on January 11, 2023 and as to the remaining on February 11, 2023. The stock option vests and is exercisable as to approximately 14% of the underlying shares on August 5, 2022, approximately 64% of the underlying shares in 28 substantially equal monthly installments beginning on September 5, 2022, and approximately 22% of the underlying shares in 12 substantially equal monthly installments thereafter. By: /s/ Andrew Reardon, Attorney-in-Fact For: Octavio Espinoza 2024-05-17